Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.44 |
| ▸ | BRAF | P15056 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | EIF2AK3 | Q9NZJ5 | 6/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160754 | 0.91 | BRAF (0.48) | HIF1ABRAFKDM4EAHREIF2AK3 | |
| SCHEMBL2564931 | 0.90 | HIF1A (0.42) | HIF1ABRAFKDM4EAHREIF2AK3 | |
| SCHEMBL4412867 | 0.85 | HSD11B1 (0.34) | HIF1AHPGDSMN1; SMN2 | |
| SCHEMBL2568666 | 0.81 | BRAF (0.45) | HIF1ABRAFKDM4EAHREIF2AK3 | |
| SCHEMBL2564378 | 0.80 | HDAC4 (0.36) | HIF1AKDM4EAHRMAPTNPC1 | |
| SCHEMBL2565160 | 0.80 | ADORA1 (0.36) | HIF1ABRAFKDM4EAHREIF2AK3 | |
| SCHEMBL2565286 | 0.80 | KDM4E (0.41) | HIF1AKDM4EAHRPLK1MAPT | |
| SCHEMBL2567820 | 0.80 | CYP2C9 (0.34) | HIF1AKDM4EAHRPLK1MAPT | |
| SCHEMBL12164455 | 0.79 | CYP2C9 (0.33) | HIF1AKDM4EAHRMAPTNPC1 | |
| SCHEMBL842839 | 0.78 | KDM4E (0.39) | HIF1AKDM4EAHRPLK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069354-B1 | Aza-benzofuranyl compounds and methods of use | GENENTECH INC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2069354-B1 | Aza-benzofuranyl compounds and methods of use | GENENTECH INC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2069354-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | HIF1A 816/4885BRAF 42/4885KDM4E 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.